Kitabis pak and Pneumonia aggravated - a phase IV clinical study of FDA data

Summary:

Pneumonia aggravated is reported as a side effect among people who take Kitabis pak (tobramycin), especially for people who are male, 10-19 old, have been taking the drug for 6 - 12 months also take Pulmozyme, and have Cystic fibrosis.

The phase IV clinical study analyzes which people have Pneumonia aggravated when taking Kitabis pak. It is created by eHealthMe based on reports of 921 people who have side effects when taking Kitabis pak from the FDA, and is updated regularly.

What is Kitabis pak?

Kitabis pak has active ingredients of tobramycin. eHealthMe is studying from 921 Kitabis pak users. Check the latest studies of Kitabis pak.

What is Pneumonia aggravated?

Pneumonia aggravated is found to be associated with 2,217 drugs and 878 conditions by eHealthMe. Check the latest studies of Pneumonia aggravated.

On Jul, 04, 2026

921 people reported to have side effects when taking Kitabis pak.
Among them, 83 people (9.01%) have Pneumonia aggravated.

Could Kitabis pak cause Pneumonia aggravated?

Among these 83 people:

How long have people been on Kitabis pak when they have Pneumonia aggravated? *

What is the gender of people who have Pneumonia aggravated when taking Kitabis pak? *

female: 50 %
male: 50 %

What is the age of people who have Pneumonia aggravated when taking Kitabis pak? *

What are other drugs people take besides Kitabis pak? *

What are other side effects people have besides Pneumonia aggravated? *

Infective Pulmonary Exacerbation Of Cystic Fibrosis (severe infective lung disease with production of abnormally thick mucus): 10 people, 12.05%
Hospitalisation: 8 people, 9.64%
Urinary Tract Infection: 5 people, 6.02%
Weight Decreased: 3 people, 3.61%
Fungal Infection: 3 people, 3.61%
Upper Respiratory Tract Infection: 3 people, 3.61%
Nausea (feeling of having an urge to vomit): 3 people, 3.61%
Sinusitis (inflammation of sinus): 3 people, 3.61%
Coughing Up Blood: 3 people, 3.61%
Respiratory Distress (difficulty in breathing): 3 people, 3.61%

What are the existing conditions these people have? *

Cystic Fibrosis (disease of the secretary glands): 50 people, 60.24%
Lung Disorder (lung disease): 9 people, 10.84%
Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 4 people, 4.82%
Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection): 3 people, 3.61%
Tracheitis (an inflammation of the trachea): 3 people, 3.61%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 3 people, 3.61%
Cystic Fibrosis Lung (fibrosis with cyst in the lung): 3 people, 3.61%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 3 people, 3.61%
Asthma: 2 people, 2.41%
Hypersensitivity: 1 person, 1.20%

* Approximation only. Some reports may have incomplete information.

Do you take Kitabis pak and have Pneumonia aggravated?

- Check whether Pneumonia aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kitabis pak:

Kitabis pak (921 reports)

Browse all side effects of Kitabis pak:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pneumonia aggravated:

Pneumonia aggravated (2,218 drugs)

Browse all the conditions that are associated with Pneumonia aggravated:

Pneumonia aggravated (878 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tobramycin (the active ingredients of Kitabis pak) and Kitabis pak (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.